CAL
NMRA icon

Capital Advisors Ltd’s Neumora Therapeutics NMRA Stock Holding History

Capital Advisors Ltd’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
145
– – ﹤0.01% 1514
2026
Q1 		$0 Hold
145
– – ﹤0.01% 1526
2025
Q4 		$0 Hold
145
– – ﹤0.01% 1502
2025
Q3 		$0 Hold
145
– – ﹤0.01% 1496
2025
Q2 		$0 Buy
145
+94
+184% +$71 ﹤0.01% 1542
2025
Q1 		$0 Buy
+51
New +$87 ﹤0.01% 1510

Other funds holding NMRA

WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AH
Addis & Hill Wayne, Pennsylvania $181M AUM 21.74% 1-Year Est. Return
LPT
Legacy Private Trust Neenah, Wisconsin $1.81B AUM 19.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

Capital Advisors Ltd's NMRA Position: Q2 2026 in Review

Capital Advisors Ltd held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 145 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1514.

Capital Advisors Ltd first reported a position in NMRA in Q1 2025 and has held it in 6 quarters since. 6 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Capital Advisors Ltd held 145 shares of Neumora Therapeutics worth $0 as of Q2 2026.
  • Capital Advisors Ltd left its Neumora Therapeutics share count unchanged in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #1514 holding.
  • Capital Advisors Ltd first reported a position in Neumora Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 6 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.